A drug approved for the treatment of chronic constipation (chronic constipation) that may slow the body pain associated with the condition, recently, Published in a study entitled "Intestinal neuropod cell GUCY2C regulates visceral pain" in the international journal Journal of Clinical Investigation, Scientists from Thomas Jefferson University and other institutions have found that, The way of action of the drug may be biologically separated, The findings may potentially help develop new therapies to precisely target visceral pain syndrome (visceral pain syndromes) other than constipation.
The researchers say, exists in the gut called GUCY2C receptor molecules can regulate the body's water and salt balance, which can adjust the softness of stool, called linalol peptide (linaclotide) constipation drugs can act on the receptor to increase the secretion of water, however, the pain of the drug seems to be not a simple result of relieving constipation, and about how all this work, the scientists put forward a variety of assumptions. Researchers Waldman et al began to clarify how the drug focused on GUCY2C receptors in a newly discovered intestinal cell nerve pod (neuropods) cell that senses stimuli and communicates closely with neurons that send pain messages to the brain.
In this study, the researchers use molecular tools from the mouse "nerve pod" cells (not other intestinal cells) from the GUCY2C receptor, changed animals will experience spontaneous visceral pain, and drug linarpeptide does not relieve animal pain symptoms, at the same time, the water secretion of the body is not affected, this means that "nerve pod" cell receptor can regulate the intestinal sensation, but also mediate the effects of drugs on the body pain. To the surprise of researchers, why this division is so distinct. It is well known that biological functions have certain redundancy, and exploring scientific research does not usually produce such clear results, which may separate two seemingly related functions, pain relief and water secretion.
Researchers said Waldman, we imagine how to develop direct targeting "nerve pod" cell therapy, we may also be able to avoid other visceral pain condition showed a major side effect, namely diarrhea, for example, with diarrhea of irritable bowel syndrome or endometriosis, "nerve pod" cells regulation of visceral pain may represent a "last common pathway". In conclusion, our results demonstrate that in the absence of GUCY2C hormones in patients with visceral pain, researchers reveal the key and specific role of "nerve pod" cellular GUCY2C signaling in the pathophysiological manifestations and the development of therapies in these pain syndromes.
